Xenon Pharmaceuticals (XENE) News Today $38.02 -0.26 (-0.67%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Allostery Investments LP Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Allostery Investments LP bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 30,000 shares of the biopharmaceutical company's stock, valued at approximately $1,17May 4 at 7:45 AM | marketbeat.comAlly Bridge Group NY LLC Cuts Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Ally Bridge Group NY LLC lessened its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 39.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 129,291 shares of the biopharmaceutical company's stock after selMay 4 at 7:45 AM | marketbeat.comBoxer Capital Management LLC Invests $23.52 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Boxer Capital Management LLC acquired a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 600,000 shares of the biopharmaceutical company's stock, valued at apprMay 4 at 6:25 AM | marketbeat.comXenon Pharmaceuticals (XENE) Projected to Post Earnings on ThursdayXenon Pharmaceuticals (NASDAQ:XENE) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-xenon-pharmaceuticals-inc-stock/)May 3 at 6:20 AM | marketbeat.comXenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors acquired 4,063 put options on the company. This represents an increase of 2,362% compared to the typical volume of 165 put options.May 3 at 1:36 AM | marketbeat.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2 at 4:57 PM | financialpost.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2 at 4:42 PM | globenewswire.comBoothbay Fund Management LLC Decreases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Boothbay Fund Management LLC decreased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 42.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,395 shares of thMay 2 at 5:12 AM | marketbeat.comInvestors Buy Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)May 1, 2025 | americanbankingnews.comFirst Light Asset Management LLC Cuts Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)First Light Asset Management LLC decreased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,160,580 shares of the biopharmaceutical compApril 30, 2025 | marketbeat.comLord Abbett & CO. LLC Buys 20,986 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Lord Abbett & CO. LLC increased its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 12.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 194,971 shares of the biopharmaceutical company's stock after buying an additional 20,986 sApril 30, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $56.78 Consensus PT from AnalystsApril 29, 2025 | americanbankingnews.comT. Rowe Price Investment Management Inc. Sells 65,977 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)T. Rowe Price Investment Management Inc. reduced its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,437,831 shares of the biopharmaceutical comApril 28, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from AnalystsShares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been given a consensus rating of "Buy" by the ten research firms that are covering the stock, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 1-year price obApril 28, 2025 | marketbeat.comXTX Topco Ltd Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)XTX Topco Ltd acquired a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 8,054 shares of the biopharmaceutical company's stock, valueApril 27, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. trimmed its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 10.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,863,473 shares of the biophApril 26, 2025 | marketbeat.comJ. Safra Sarasin Holding AG Invests $697,000 in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)J. Safra Sarasin Holding AG bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 17,786 shares of the biopharmaceutical company's stock, valued at approximatelyApril 26, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews.com to "Hold" RatingApril 26, 2025 | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews.com to Hold RatingStockNews.com upgraded Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday.April 26, 2025 | marketbeat.comEversept Partners LP Acquires New Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Eversept Partners LP purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 155,540 shares of the biopharmaceutical company's stock, valueApril 24, 2025 | marketbeat.comCapital World Investors Sells 387,000 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Capital World Investors trimmed its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 14.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 2,294,537 shares of the biopharmaceutical company's stock after selling 387,0April 24, 2025 | marketbeat.comRock Springs Capital Management LP Has $49.07 Million Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Rock Springs Capital Management LP lowered its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,251,859 shares of the biopharmaceutical compApril 23, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Capital International InvestorsCapital International Investors decreased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,547,210 shares oApril 22, 2025 | marketbeat.comMarshall Wace LLP Cuts Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Marshall Wace LLP trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 24.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 899,718 shares of the biopharmaceutical compaApril 21, 2025 | marketbeat.comTraders Purchase Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of some unusual options trading on Wednesday. Traders purchased 4,063 put options on the stock. This is an increase of 2,362% compared to the typical volume of 165 put options.April 19, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of XENE Q1 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a research note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the bioApril 18, 2025 | marketbeat.comWalleye Capital LLC Has $8.70 Million Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Walleye Capital LLC boosted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 111.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 221,982 shares of the biopharmaceutical coApril 18, 2025 | marketbeat.comXenon- A Later Stage StoryApril 18, 2025 | seekingalpha.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Affinity Asset Advisors LLCAffinity Asset Advisors LLC raised its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,161,237 shares of the biopharmaceutApril 17, 2025 | marketbeat.comStockNews.com Downgrades Xenon Pharmaceuticals (NASDAQ:XENE) to SellStockNews.com downgraded Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday.April 17, 2025 | marketbeat.comRussell Investments Group Ltd. Cuts Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Russell Investments Group Ltd. lessened its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 213,696 shares oApril 15, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Fmr LLCFmr LLC raised its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,525,290 shares of the biopharmaceutical company's stock after purchasing an additionalApril 13, 2025 | marketbeat.comFederated Hermes Inc. Sells 177,700 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Federated Hermes Inc. trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 24.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 558,500 shares of the biopharmaceutical company's stock afterApril 11, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month Low - What's Next?Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 52-Week Low - Should You Sell?April 10, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Price Up 5.2% - Here's What HappenedXenon Pharmaceuticals (NASDAQ:XENE) Trading 5.2% Higher - Here's WhyApril 10, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 22,644 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)ADAR1 Capital Management LLC increased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 81.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,547 shares of the biopharmApril 9, 2025 | marketbeat.comExodusPoint Capital Management LP Has $2.70 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)ExodusPoint Capital Management LP trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 73.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,884 shares of the biopharmaceApril 9, 2025 | marketbeat.comAtika Capital Management LLC Lowers Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Atika Capital Management LLC reduced its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 42.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,600 shares of the bioApril 8, 2025 | marketbeat.comFranklin Resources Inc. Boosts Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Franklin Resources Inc. grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 575,590 shares of the biopharmaceutical company's stock after purchaApril 8, 2025 | marketbeat.comAlliancebernstein L.P. Raises Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Alliancebernstein L.P. lifted its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,443,180 shares of the biopharmaceutical company's stock afterApril 7, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)JPMorgan Chase & Co. grew its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 38.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,356,895 shares of the bApril 7, 2025 | marketbeat.comPrudential Financial Inc. Acquires 24,956 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Prudential Financial Inc. increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 177.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,000 shares of the biopharmaceuticalApril 7, 2025 | marketbeat.comRaymond James Financial Inc. Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Raymond James Financial Inc. purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,331 shares ofApril 7, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.comStockNews.com cut shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday.April 7, 2025 | marketbeat.comWellington Management Group LLP Sells 65,836 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Wellington Management Group LLP cut its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,777,611 shares of the biopharmaceutical companyApril 5, 2025 | marketbeat.comKLP Kapitalforvaltning AS Purchases Shares of 12,800 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)KLP Kapitalforvaltning AS acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 12,800 shares of the biopharmaceutical company's stock, valued at approximately $502April 5, 2025 | marketbeat.comXenon Pharmaceuticals Looks Attractive Before Epilepsy DataApril 4, 2025 | seekingalpha.comXenon Pharmaceuticals (NASDAQ:XENE) Sees Large Volume Increase - What's Next?Xenon Pharmaceuticals (NASDAQ:XENE) Sees Unusually-High Trading Volume - Here's What HappenedApril 4, 2025 | marketbeat.comXenon Slides Ahead of San Diego ConcferenceApril 4, 2025 | baystreet.caXenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025April 4, 2025 | globenewswire.com Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address XENE Media Mentions By Week XENE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XENE News Sentiment▼1.240.73▲Average Medical News Sentiment XENE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XENE Articles This Week▼135▲XENE Articles Average Week Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Ascendis Pharma A/S News Viatris News Qiagen News Roivant Sciences News Revolution Medicines News Lantheus News BridgeBio Pharma News TG Therapeutics News Legend Biotech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XENE) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XENE Stock Free XENE Stock Alerts